News
Keytruda Approved as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
The approval was based on data from the phase 3 KEYNOTE-826 trial.
Your search for bevacizumab returned 6 results
ESMO 2021, News
Immunotherapy Significantly Improved Survival in Recurrent/Metastatic Cervical Cancer
The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.
ESMO 2021, News
Adding Bevacizumab to Erlotinib Prolongs PFS in Non-Squamous Non-Small Cell Lung Cancer
There was no improvement in overall survival with bevacizumab.
ESMO 2021, News
Pembrolizumab Plus Chemo ± Bevacizumab Prolonged Survival in Cervical Cancer
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
Drugs in the Pipeline
Tisotumab Vedotin Under Review for Recurrent or Metastatic Cervical Cancer
Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.
News
Anti-VEGF Injections May Reduce Glaucoma Burden for Some
Study shows reductions in intraocular pressures and antiglaucoma medication use.
